The early data on T-Dxd in NSCLC originated from a solid non-breast and non-gastric cancers dose-expansion phase I study that enrolled 18 patients with HER2-mutant/HER2-expressing NSCLC. The gene discussed is ERBB2; the disease is gastric cancer.